李斌,教授、博导,
“
南山学者
”
杰出人才,广州医科大学附属第五医院医学研究中心主任,广东
省生物靶向诊治与康复重点实验室副主任。从教以来,曾指导
4
名博士后、
6
名博士研究生、
19
名硕
士研究生和 5 名本科生。指导的学生曾获得“国家奖学金”、“一等奖学金”和“广东省优秀毕业生”等荣
誉,并在国内外知名期刊上发表论文,以优秀的成绩毕业。担任《临床研究设计类型与临床问题》和
《科研思路与方法》本科课程授课,带领本科生了解医学科研。现从事肿瘤生物学的基础和应用研究,
主要基于细胞动物模型和多组学分析,进行肿瘤靶点筛选鉴定、翻译后修饰表观遗传研究及靶向干预
探索。主持国家自然科学基金、国家重点研发计划子课题及省市项目等。近五年,以通讯作者发表
SCI
论文 30 余篇,其中 IF>10 文章 18 篇,包括 Cell Res、Cancer Res (2022, 2023) 、Adv Sci (2020, 2022)、
Nature Commun
、
Clin Cancer Res
、
Signal Transduct Target Ther (2021, 2023)
、
Cell Discovery
、
Oncogene
、
EBioMedicine、Cancer Commun、Acta Pharm Sin B 等,系列工作多次被 Nature、Nature Cell Biology 等
引用。已授权中国专利 14 项, 申请 PCT 专利 2 项。担任香港大学医学院荣誉助理教授,在中国抗癌协
会肿瘤转移专委会、中国抗癌协会肿瘤标志专委会、中国病理生理学会蛋白质修饰与疾病专委会等国
家级学会担任常委、委员等,担任 Signal Transduct Target Ther、Acta Pharm Sin B 等学术期刊编委。
1. Liao L#, He Y#, Li SJ#, Yu XM#, Liu ZC#, Liang YY, Yang H, Yang H, Zhang GG, Deng CM, Wei
X, Zhu YD, Xu TY, Zheng CC, Cheng C, Li A, Li ZG, Liu JB, Li B* (2023) . Lysine
2-hydroxyisobutyrylation of NAT10 promotes cancer metastasis in an ac4C-dependent manner. Cell
Research.33(5):355-371.
2. Deng CM #, Zhang GG #, Liu QW #, Xu JJ #, Liu ZC, Yang J, Xu TY, Li ZG, Li B* (2023).
ANO1reprograms cholesterol metabolism and the tumor microenvironment to promote cancer
metastasis. Cancer Research. 2;83(11):1851-1865.
3. Yu XM#, Li SJ#, Yao ZT#, Xu JJ#, Zhang GG, Liu ZC, Ding PB, Jiang ZL, Wei X, PZhao LP, Shi
XY, Li ZG, Xu WW, Li B* (2023). N4-acetylcytidine modification of IncRNA CTC490G23.2 promotes
cancer metastasis through interactingwith PTBP1 to increase CD44 alternative splicing. Oncogene.
42(14):1101-1116.
4. Tan XP#, He Yan#, Yang J, Wei X, Fan YL, Zhang GG, Zhu YD, Li ZQ, Liao HX, Qin DJ, Guan XY,
Li B*(2023). Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and
suppresses liver cancer progression. Signal Transduction and Targeted Therapy. 9;8(1):14.
5. Xu WW#, Liao L#, Dai W, Zheng CC, Tan XP, He Y, Zhang QH, Huang ZH, Chen WY, Qin YR,
Chen KS, He ML, Law S, Lung ML*, He QY*, Li B*(2023). Genome-wide CRISPR/Cas9 screening
identifies a targetable MEST-PURA interaction in cancer metastasis. EBioMedicine. 92(10):104587.
6. He Y#, Zheng CC#, Yang J#, Li SJ#, Xu TY, Wei X, Chen WY, Jiang ZL, Xu JJ, Zhang GG, Cheng
C, Chen KS, Shi XY, Qin DJ, Liu JB, Li B*(2023). Lysine butyrylation of HSP90 regulated by KAT8 and
HDAC11 confers chemoresistance. Cell Discov.
7. Zhao LP; Rao XN; Zheng RR; Huang CY; Kong RJ; Cheng H*; Li B*; Li, SY*(2023). Carrier free
Nano-PROTACs to Amplify Photodynamic Therapy Induced DNA Damage through BRD4 Degradation.
Nano Letters.
8. Zheng CC#, Liao L#, Liu YP#, Yang YM, He Y, Zhang GG, Li S, Liu T, Xu WW*, Li B*(2022).
Blockade of nuclear β-catenin signaling via direct targeting of RanBP3 with NU2058 induces cell
senescence to suppress colorectal tumorigenesis. Advanced Science. 9(34):e2202528.
9. Liao L#, He Y#, Li SJ, Zhang GG, Yu W, Yang J, Huang ZJ, Zheng CC, He QY, Li Y, Li B*(2022).
Anti-HIV drug elvitegravir suppresses cancer metastasis via increased proteasomal degradation of m6A
methyltransferase METTL3. Cancer Research. 5;82(13):2444-2457.
10. Zheng CC#, Yu XM#, Liang YY, Zhu YD, He Y, Liao L, Wang DK, Yang YM, Yin XF, Li A, He
QY*, Li B*(2022). Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer
tumorigenesis in an AMPK/FOXO3a/Bim-dependent manner. Acta Pharmaceutica Sinica B.
12(3):1271-1287.